Your browser doesn't support javascript.
loading
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Moore, M; Gill, S; Asmis, T; Berry, S; Burkes, R; Zbuk, K; Alcindor, T; Jeyakumar, A; Chan, T; Rao, S; Spratlin, J; Tang, P A; Rothenstein, J; Chan, E; Bendell, J; Kudrik, F; Kauh, J; Tang, S; Gao, L; Kambhampati, S R P; Nasroulah, F; Yang, L; Ramdas, N; Binder, P; Strevel, E.
Affiliation
  • Moore M; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver malcolm.moore@bccancer.bc.ca.
  • Gill S; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver.
  • Asmis T; The Ottawa Hospital Cancer Centre, Ottawa.
  • Berry S; Sunnybrook Odette Cancer Centre, Toronto.
  • Burkes R; Mount Sinai Hospital, Toronto.
  • Zbuk K; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton.
  • Alcindor T; Department of Oncology, McGill University, Montréal.
  • Jeyakumar A; Atlantic Clinical Cancer Research Unit, QEII Health Sciences Centre, Nova Scotia Cancer Centre, Halifax.
  • Chan T; Fraser Valley Cancer Centre, British Columbia Cancer Agency, Surrey.
  • Rao S; Kelowna Cancer Centre, British Columbia Cancer Agency, Kelowna.
  • Spratlin J; Cross Cancer Institute, Edmonton.
  • Tang PA; Tom Baker Cancer Centre, Calgary.
  • Rothenstein J; RSM Durham Regional Cancer Centre, Lakeridge Health Oshawa, Oshawa, Canada.
  • Chan E; Vanderbilt-Ingram Cancer Center, Nashville.
  • Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville.
  • Kudrik F; South Carolina Oncology Associates, Sarah Cannon Research Institute, Columbia.
  • Kauh J; Eli Lilly and Company, Indianapolis, USA.
  • Tang S; Eli Lilly and Company, Indianapolis, USA.
  • Gao L; Eli Lilly and Company, Indianapolis, USA.
  • Kambhampati SR; Eli Lilly and Company, Indianapolis, USA.
  • Nasroulah F; Eli Lilly and Company, Indianapolis, USA.
  • Yang L; Eli Lilly and Company, Indianapolis, USA.
  • Ramdas N; Eli Lilly and Company, Indianapolis, USA.
  • Binder P; Eli Lilly and Company, Indianapolis, USA.
  • Strevel E; Trillium Health Partners, Mississauga, Canada.
Ann Oncol ; 27(12): 2216-2224, 2016 12.
Article in En | MEDLINE | ID: mdl-27733377
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication: Reino Unido